ESBATech AG has been awarded US Patent No. 6,821,728, “Screening system.”
Inventors listed on the patent are Dominik Escher and Alcide Barberis.
According to its abstract, the patent protects a screening system for screening effector peptides that can act as agonists or antagonists, as well as means to produce such a screening system, in particular a specific DNA library encoding peptides. In order to perform the screening, host cells comprising a selection system are transformed with the DNA library, and the thus obtained system is then cultivated under conditions selectively allowing survival of cells with desired interaction, the abstract states.
Panomics has been awarded US Patent No. 6,821,737, “Method for screening for drug candidates for modulating transcription factor activity.”
Xianqiang Li is the inventor listed on the patent.
According to its abstract, the patent provides methods and kits for screening for transcription factor modulators efficiently. In one aspect, the method can be employed to profile multiple, different transcription factors activated in a sample in the presence of each of the transcription factor modulators, the abstract states. Comparison of the activated transcription factor profiles in the presence and absence of the modulator identifies the transcription factor modulator that modulates the activation of specific transcription factors, the abstract states.
Becton Dickinson has been awarded US Patent No. 6,821,740, “Flow cytometric methods for the concurrent detection of discrete functional conformations of PRB in single cells.”
Inventors listed on the patent are Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan, and Stefan Gruenwald.
According to its abstract, the patent provides methods, reagents, and kits that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB, the abstract states. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for anti-proliferative and anti-neoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided, the abstract states.